Navigation Links
Guggenheim Securities Expands Healthcare Equity Research Team
Date:8/14/2012

NEW YORK, Aug. 14, 2012 /PRNewswire/ -- Guggenheim Partners, LLC ("Guggenheim"), a global diversified financial services firm, today announced two appointments to its Equity Research team. Louise Chen, Managing Director, will cover the specialty pharmaceutical sector, and Bret Holley, Managing Director, will cover the biotechnology sector. Based in New York, both analysts will report to Raymond Katz, Director of Equity Research for Guggenheim Partners.

"We are excited to have two seasoned and talented analysts join our team. Guggenheim's growing equity research practice is strongly positioned to offer investors and the marketplace timely and informed analysis of the healthcare industry as it undergoes unprecedented change," said Mr. Katz.

Ms. Chen joins Guggenheim from New York-based firm Auriga USA LLC, where she was a Managing Partner and Senior Analyst of Equity Research. At Auriga, Ms. Chen covered small-to-mid cap specialty pharmaceutical companies such as Teva Pharmaceutical Industries, Forest Laboratories and Warner Chilcott. Prior to Auriga, she spent several years at investment bank Canaccord Genuity, where she led the coverage of 14 leading specialty pharmaceutical companies. Earlier in her career, Ms. Chen worked as a Vice President of Equity Research at Morgan Stanley and as a business development executive at Dr. Reddy's Laboratories.

Mr. Holley joins Guggenheim with more than 15 years of experience in the biotechnology sector.  He was most recently a Managing Director and Senior Research Analyst at Oppenheimer & Co., formerly CIBC World Markets, where  he spent more than a decade leading the coverage of some of the world's largest biotechnology companies, including Amgen Inc., Celgene Corp., Gilead Sciences and ImmunoGen, Inc. Earlier in his career, Mr. Holley was a bioinformatics application architect at Ingenuity Systems where he developed biotechnology data software and worked with major biotech and pharmaceutical companies.

About Guggenheim Partners
Guggenheim Partners, LLC is a privately held global financial services firm with more than $160 billion in assets under management. The firm provides asset management, investment banking and capital markets services, insurance, institutional finance and investment advisory solutions to institutions, governments and agencies, corporations, investment advisors, family offices and individuals. Guggenheim Partners is headquartered in New York and Chicago and serves clients around the world from more than 25 offices in nine countries. For more information about Guggenheim Partners, visit www.guggenheimpartners.com.

Contacts:
Torie von Alt
Guggenheim Partners
+1 212 378 6216
Torie.vonalt@guggenheimpartners.com

Or

Tripp Kyle / Mary Zimmerman
Brunswick Group
+1 212 333 3810
guggenheim@brunswickgroup.com


'/>"/>
SOURCE Guggenheim Partners, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Hill-Rom to Participate in the Deutsche Bank Securities Health Care Conference
2. Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
3. Omeros to Present at Deutsche Bank Securities Health Care Conference
4. Volcano Corporation Presentation At JMP Securities Conference To Be Webcast
5. Uroplasty to Present at the 11th Annual JMP Securities Research Conference
6. Cumberland Pharmaceuticals To Present At The 2012 Wells Fargo Securities Healthcare Conference In Boston
7. Quest Diagnostics To Speak At The Wells Fargo Securities 2012 Healthcare Conference
8. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
9. ViroPharma To Participate In The JMP Securities Healthcare Conference
10. Isis Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
11. Uroplasty To Present At The JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at http://www.rebound-solution.com/ ...
(Date:9/25/2017)... Sept. 25, 2017   Montrium , an ... solutions, today—from the IQPC Trial Master Files & ... NL)—announced that EastHORN Clinical Services has selected ... and TMF management. EastHORN, a leading European contract ... to increase transparency to enable greater collaboration with ...
(Date:9/19/2017)... medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound energy ... ... Jim Bertolina, PhD ... Tom Tefft ... executive Josh Stopek , PhD, who has led R&D and business development teams at ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
Breaking Medicine News(10 mins):